PubMed

Sutter Health and Charles R. Drew University Partner to Address Physician Shortage and Health Inequities Across California

Retrieved on: 
Wednesday, March 6, 2024

"This unique collaboration marks a significant step toward building a more equitable health care system in California,” said Dr. David M. Carlisle, president and CEO of Charles R. Drew University.

Key Points: 
  • "This unique collaboration marks a significant step toward building a more equitable health care system in California,” said Dr. David M. Carlisle, president and CEO of Charles R. Drew University.
  • Additionally, it will fund HEARE over the next five years to help accelerate interventions that address root causes of inequities.
  • Sutter Health and CDU will also explore additional opportunities to broaden the partnership and train more physicians with future initiatives.
  • This investment is part of Sutter’s broader commitment to address California’s growing physician shortage and persistent health inequities by enhancing access to culturally competent care for under-represented populations.

Western Blotting Market on the Rise, Expected to Hit $2.1 Billion by 2028: Strategic Analysis by BCC Research

Retrieved on: 
Wednesday, February 7, 2024

BOSTON, Feb. 7, 2024 /PRNewswire/ -- Diving into the world of scientific discovery, Western Blotting is like a superhero in the lab, helping researchers unravel the mysteries of proteins in complex mixtures. Picture it as a 'molecular fingerprint' that lets scientists sleuth around, uncovering the who, what, and how many proteins. This technique isn't just a fancy lab trick – it's a powerhouse in understanding diseases, crafting new drugs, and decoding the intricate dance of biological processes. With its fingerprints all over biology, medicine, and biotech, Western Blotting isn't just a tool; it's a key player in the game of life sciences, offering researchers a versatile way to unlock groundbreaking molecular insights.

Key Points: 
  • Embark on a comprehensive journey into the dynamic realm of Western Blotting with our latest report.
  • The journey through time has witnessed transformative modifications, with innovations like multiplex Western Blotting and quantitative techniques enriching its capabilities.
  • Increasing Prevalence of Target Diseases: One of the primary driving forces propelling the Western Blotting market is the escalating prevalence of target diseases.
  • This synergy between government funding and Western Blotting underscores the critical role this method plays in shaping the landscape of biomedical research.

Shriners Children's Doctor Alerts Parents of Overlooked Dangers of Microwave Soups and Noodles During National Burn Awareness Week

Retrieved on: 
Monday, February 5, 2024

Dr. David Greenhalgh, Chief of Burns at Shriners Children's Northern California, has spent more than 35 years working with pediatric burn patients.

Key Points: 
  • Dr. David Greenhalgh, Chief of Burns at Shriners Children's Northern California, has spent more than 35 years working with pediatric burn patients.
  • Now, the primary culprit is scalding injuries from simple items people forget are dangerous, such as hot liquids and microwave foods.
  • He says while convincing companies to change their packaging for products is a difficult and lengthy process, parents need to be aware of the dangers.
  • All three Shriners Children's burn care locations across the country are accredited by the American Burn Association (ABA) and the American College of Surgeons (ACS) as verified pediatric burn centers.

JMIR MEDICAL INFORMATICS INVITES SUBMISSIONS ON AI LANGUAGE MODELS IN HEALTH CARE

Retrieved on: 
Friday, February 2, 2024

TORONTO, Feb. 2, 2024 /PRNewswire/ -- JMIR Publications is pleased to announce a new section titled, "AI Language Models in Health Care" in JMIR Medical Informatics .

Key Points: 
  • TORONTO, Feb. 2, 2024 /PRNewswire/ -- JMIR Publications is pleased to announce a new section titled, "AI Language Models in Health Care" in JMIR Medical Informatics .
  • JMIR Medical Informatics invites contributions that delve into the reliability, transparency, and evidence-based effectiveness of AI language models, shedding light on their real-world impact on patient care, medical education, research, and health care systems at large.
  • AI language models hold substantial promise within health care settings but also come with challenges associated with their integration.
  • Accordingly, we encourage submissions on topics including but not limited to the following:
    Outcomes of AI language model implementation, including acceptability, adoption, feasibility, cost-effectiveness, sustainability, safety, and usability within health care settings
    All submissions will be rigorously peer reviewed, and accepted articles will be published as part of the " AI Language Models in Health Care " section.

NeuroQure Acquires Patents to Detect Autism in Newborns with a Skin Sample

Retrieved on: 
Wednesday, December 13, 2023

The company has acquired the exclusive rights to license a patent portfolio from the UC Irvine Center for Autism Research and Translation (CART).

Key Points: 
  • The company has acquired the exclusive rights to license a patent portfolio from the UC Irvine Center for Autism Research and Translation (CART).
  • Ph.D. and his team during his tenure as Founding Director of CART.
  • In securing the exclusive license of UC Irvine's CART patents, NeuroQure is poised to revolutionize the landscape of Autism diagnostics.
  • The company's dedication to addressing the gap in current technologies underscores its commitment to transform the lives of children and families affected by ASD.

Truveta welcomes Patrick Caubel, Pfizer Chief Safety Officer, to its Board of Directors

Retrieved on: 
Monday, December 4, 2023

The Truveta Board of Directors ensures the data and analytics company is operating in pursuit of its mission, providing strategic, scientific, and operational direction.

Key Points: 
  • The Truveta Board of Directors ensures the data and analytics company is operating in pursuit of its mission, providing strategic, scientific, and operational direction.
  • Today, Truveta welcomes Dr. Patrick Caubel as an independent board member.
  • “We welcome Dr. Caubel and his unique experience to the Truveta board.”
    Dr. Caubel was elected to Truveta’s board by the current health system-led board, and not appointed by Pfizer.
  • In his board capacity, Dr. Caubel will not have access to any customer’s research with Truveta.

RetinalGeniX™ Technologies Inc. Announces the Submission of Two Provisional Patent Applications For Investigational Therapeutic Drugs

Retrieved on: 
Thursday, November 9, 2023

PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.

Key Points: 
  • PETALUMA, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- RetinalGeniX™ Technologies Inc. (OTCQB:RTGN) (“RetinalGeniX” or the “Company”), today announced that it has submitted two provisional patent applications to the US Patent Office for its investigational therapeutic drug candidates RTG-2023 and RTG-2024.
  • There are two forms of the disease; wet AMD and dry AMD.
  • ADI estimates there are over 10 million new cases of dementia each year worldwide, implying one new case every 3.2 seconds.
  • The Company’s novel approach includes the use of high-resolution retinal imaging and pharmacogenetic mapping to be combined with the promise of these investigational drugs.

Kirin iMUSE Immune Care and Healthya Visceral Fat Down will go on sale on Tuesday, November 28!

Retrieved on: 
Monday, November 27, 2023

Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).

Key Points: 
  • Kirin Holdings Company, Limited (TOKYO:2503) will launch a dual-care functional food supplement Kirin iMUSE Immuno-Care and Healthya Visceral Fat Down on November 28 (Tuesday).
  • This product is a collaboration between Kirin iMUSE, Japan’s first*1 immune care brand, and Kao Healthya, Japan’s first*1 body fat care beverage brand from Kao Corporation (TOKYO:4452), and will be sold at drugstores nationwide and through Kirin Kyowa Hakko Bio mail order.
  • We are developing a broad lineup of functional food products with immune function claims to help customers solve their health issues.
  • “Kirin iMUSE Immunity Care and Healthya Visceral Fat Down,” which is about to go on sale, is a product born from the joint research project.

Japan’s First Discovery*1 on Visceral Fat and Immune Activity in Joint Research by Kirin Holdings and Kao

Retrieved on: 
Friday, November 24, 2023

Visceral fat area: Based on a median value of 77 cm2 for all subjects, those with visceral fat less than 77 cm2 were defined as the low visceral fat group, and those with visceral fat greater than 77 cm2 as the high visceral fat group.

Key Points: 
  • Visceral fat area: Based on a median value of 77 cm2 for all subjects, those with visceral fat less than 77 cm2 were defined as the low visceral fat group, and those with visceral fat greater than 77 cm2 as the high visceral fat group.
  • For the first time in the world, this collaboration found that people with high visceral fat area levels had low pDC activity.
  • It was also suggested that visceral fat area and pDC activity, respectively, affect susceptibility to novel coronavirus infection and influenza, and that people with high visceral fat area and low pDC activity are particularly susceptible to these diseases.
  • Thus, it can be said that it is important for people with high visceral fat area values and low pDC activity to address both visceral fat mass and immune function.

KATE FARMS APPOINTS PHYSICIAN AND REGISTERED DIETITIAN CHRISTINA J. VALENTINE TO CHIEF MEDICAL OFFICER POST

Retrieved on: 
Wednesday, November 8, 2023

SANTA BARBARA, Calif., Nov. 8, 2023 /PRNewswire/ -- Chairman and Chief Executive Officer of Kate Farms Brett Matthews announced today the company has named Dr. Christina J. Valentine as its new Chief Medical Officer.

Key Points: 
  • SANTA BARBARA, Calif., Nov. 8, 2023 /PRNewswire/ -- Chairman and Chief Executive Officer of Kate Farms Brett Matthews announced today the company has named Dr. Christina J. Valentine as its new Chief Medical Officer.
  • Dr. Valentine is responsible for developing the vision and strategy for the Science and Clinical division, in alignment with Kate Farms' overall business strategy.
  • Dr. Valentine most recently served as Chief Medical Officer, Medical Affairs at Reckitt/Mead Johnson Nutrition.
  • "Our Chief Medical Officer is a critically important role at Kate Farms, requiring a combination of medical nutrition, clinical research and commercial expertise," said Matthews.